

FEBRUARY 4, 2013

TiGenix to Present at Key Conferences H1 2013

Leuven (BELGIUM) – February 4, 2013 – TiGenix (Euronext Brussels: TIG), a leader in the field of cell therapy, announced today that during the first half of 2013 the company will present at a number of key events in Europe and the U.S. geared at investor, industry, and academic audiences to highlight the commercial potential of ChondroCelect®, the only approved cell therapy in Europe, and of the company's innovative proprietary allogeneic stem cell platform with programs in Phase II, and III for respectively the treatment of rheumatoid arthritis (Cx611) and perianal fistulas in Crohn's disease (Cx601).

February 11-12

BIO CEO Investor Conference, The Waldorf Astoria, New York, NY, U.S.

Presenter: Eduardo Bravo, CEO

Date & time: Tuesday, February 12, 8:30 – 8:55

Room: Room Conrad

[Click here for access to live webcast](#) (registration free, but required)

Replay available 1 hour after live event; archived webcast expires May 12, 2013

February 19

8th Annual Stem Cell Summit, Battery Gardens, Battery Park, New York, NY, U.S.

Presenter: Eduardo Bravo, CEO

Date & time: Tuesday, February 19, 12:05 – 12:35

March 11-13

BIO-Europe Spring, Centre Convencions Internacional, Barcelona, Spain

Attendees: Eduardo Bravo, CEO, Claudia Jiménez, Senior Director Corporate Development

March 16

KBC Bolero/Flanders Bio Retail Event, KBC Tower, Ghent, Belgium

Presenter: Eduardo Bravo, CEO

March 19

KBC Healthcare Conference, Brussels, Belgium

Attendees: Eduardo Bravo, CEO, Claudia D'Augusta, CFO

March 23

Dag van de Belegger, KBC Private Banking, Leuven, Belgium

Presenter: Wilfried Dalemans, CTO

Location: Archipel Business Center

Date & time: Saturday, March 23, 11:45 – 12:30

April 15-16

8th edition European Smallcap Event, Paris, France

Attendees: Eduardo Bravo, CEO, Claudia D'Augusta, CFO

April 17

BioCapital, The Grand, Amsterdam, the Netherlands

Presenter: Claudia D'Augusta, CFO

April 17

RegenMed Investor Day, New York, NY, U.S.

Presenter: Eduardo Bravo, CEO

April 22-25

BIO International Convention, McCormick Place, Chicago, Illinois, U.S.

Attendee: Claudia Jimenez, Senior Director Corporate Development

April 23

6th Annual Kempen & Co Healthcare Conference, Amsterdam, the Netherlands

Attendee: Claudia D'Augusta, CFO

May 21-23

World Stem Cell & Regenerative Medicine Congress, Victoria Plaza, London, UK.

Presenter: Eduardo Bravo, CEO

Date & time: Tuesday, May 21, 10:05 – 10:30

Title: Commercial financing: exploiting translational funding opportunities

May 22-23

BioEquity Europe 2013, Stockholm, Sweden

Presenter: Eduardo Bravo, CEO

May 30

Knowledge for Growth, ICC Ghent, Belgium

Attendee: Wilfried Dalemans, CTO

For more information:

Eduardo Bravo

Chief Executive Officer

eduardo.bravo@tigenix.com

Claudia D'Augusta

Chief Financial Officer

claudia.daugusta@tigenix.com

Hans Herklots

hans.herklots@tigenix.com

+32 16 39 60 97

About TiGenix

TiGenix NV (Euronext Brussels: TIG) is a leading European cell therapy company with a marketed product for cartilage repair, ChondroCelect®, and a strong pipeline with clinical stage allogeneic adult stem cell programs for the treatment of autoimmune and inflammatory diseases. TiGenix is based out of Leuven (Belgium) and has operations in Madrid (Spain), and Sittard-Geleen (the Netherlands). For more information please visit www.tigenix.com.

Forward-looking information

This document may contain forward-looking statements and estimates with respect to the anticipated future performance of TiGenix and the market in which it operates. Certain of these statements, forecasts and estimates can be recognised by the use of words such as, without limitation, "believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will" and "continue" and similar expressions. They include all matters that are not historical facts. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond TiGenix' control. Therefore, actual results, the financial condition, performance or achievements of TiGenix, or industry results, may turn out to be materially different from any future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of the publication of this document. TiGenix

disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in TiGenix' expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement, forecast or estimate is based, except to the extent required by Belgian law.